Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
NVG-291 by NervGen Pharma for Spinal Cord Injury: Likelihood of Approval
NVG-291 is under clinical development by NervGen Pharma and currently in Phase II for Spinal Cord Injury. According to GlobalData,...